Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : SEngine is also utilizing its precision oncology platform to inform drug discovery via strategic collaborations with pharma companies as well as, top cancer centers such as Dana-Farber and Gustave Roussy, while advancing its own pipeline of novel targete...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 28, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Oncodesign
Deal Size : Undisclosed
Deal Type : Collaboration
Details : SEngine and Oncodesign have initiated a joint research collaboration to evaluate the feasibility to convert the already identified Nanocyclix® inhibitor series into drug candidates that are likely to be effective in the clinic.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Oncodesign
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
